Literature DB >> 27184239

Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts.

Lee Pedzisa1, Xiuling Li, Christoph Rader, William R Roush.   

Abstract

Conventional antibody-drug conjugates (ADCs) are heterogeneous mixtures that have poor pharmacokinetic properties and decreased efficacy relative to homogenous ADCs. Furthermore, ADCs that are maleimide-based often have inadequate circulatory stability, which can result in premature drug release with consequent off-target toxicities. Selenocysteine-modified antibodies have been developed that allow site-specific antibody conjugation, yielding homogeneous ADCs. Herein, we survey several electrophilic functional groups that react with selenocystine with high efficiency. Several of these result in conjugates with stabilities that are superior to maleimide conjugates. Among these, the allenamide functional group reacts with notably high efficiency, leads to conjugates with remarkable stability, and shows exquisite selectivity for selenocysteine conjugation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27184239      PMCID: PMC4887430          DOI: 10.1039/c6ob00775a

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  32 in total

Review 1.  Glutathione metabolism and its implications for health.

Authors:  Guoyao Wu; Yun-Zhong Fang; Sheng Yang; Joanne R Lupton; Nancy D Turner
Journal:  J Nutr       Date:  2004-03       Impact factor: 4.798

2.  Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Authors:  Kevin J Hamblett; Peter D Senter; Dana F Chace; Michael M C Sun; Joel Lenox; Charles G Cerveny; Kim M Kissler; Starr X Bernhardt; Anastasia K Kopcha; Roger F Zabinski; Damon L Meyer; Joseph A Francisco
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

3.  Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag.

Authors:  Peng Wu; Wenqing Shui; Brian L Carlson; Nancy Hu; David Rabuka; Julia Lee; Carolyn R Bertozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

4.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Authors:  Jagath R Junutula; Helga Raab; Suzanna Clark; Sunil Bhakta; Douglas D Leipold; Sylvia Weir; Yvonne Chen; Michelle Simpson; Siao Ping Tsai; Mark S Dennis; Yanmei Lu; Y Gloria Meng; Carl Ng; Jihong Yang; Chien C Lee; Eileen Duenas; Jeffrey Gorrell; Viswanatham Katta; Amy Kim; Kevin McDorman; Kelly Flagella; Rayna Venook; Sarajane Ross; Susan D Spencer; Wai Lee Wong; Henry B Lowman; Richard Vandlen; Mark X Sliwkowski; Richard H Scheller; Paul Polakis; William Mallet
Journal:  Nat Biotechnol       Date:  2008-07-20       Impact factor: 54.908

5.  Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Jagath R Junutula; Kelly M Flagella; Richard A Graham; Kathryn L Parsons; Edward Ha; Helga Raab; Sunil Bhakta; Trung Nguyen; Debra L Dugger; Guangmin Li; Elaine Mai; Gail D Lewis Phillips; Hajime Hiraragi; Reina N Fuji; Jay Tibbitts; Richard Vandlen; Susan D Spencer; Richard H Scheller; Paul Polakis; Mark X Sliwkowski
Journal:  Clin Cancer Res       Date:  2010-08-30       Impact factor: 12.531

6.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

7.  Molecularly defined antibody conjugation through a selenocysteine interface.

Authors:  Thomas Hofer; Lauren R Skeffington; Colby M Chapman; Christoph Rader
Journal:  Biochemistry       Date:  2009-12-22       Impact factor: 3.162

8.  Contribution of linker stability to the activities of anticancer immunoconjugates.

Authors:  Stephen C Alley; Dennis R Benjamin; Scott C Jeffrey; Nicole M Okeley; Damon L Meyer; Russell J Sanderson; Peter D Senter
Journal:  Bioconjug Chem       Date:  2008-03-04       Impact factor: 4.774

9.  An engineered selenocysteine defines a unique class of antibody derivatives.

Authors:  Thomas Hofer; Joshua D Thomas; Terrence R Burke; Christoph Rader
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

10.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Authors:  Gail D Lewis Phillips; Guangmin Li; Debra L Dugger; Lisa M Crocker; Kathryn L Parsons; Elaine Mai; Walter A Blättler; John M Lambert; Ravi V J Chari; Robert J Lutz; Wai Lee T Wong; Frederic S Jacobson; Hartmut Koeppen; Ralph H Schwall; Sara R Kenkare-Mitra; Susan D Spencer; Mark X Sliwkowski
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 13.312

View more
  2 in total

1.  Utilizing Selenocysteine for Expressed Protein Ligation and Bioconjugations.

Authors:  Jun Liu; Qingqing Chen; Sharon Rozovsky
Journal:  J Am Chem Soc       Date:  2017-02-27       Impact factor: 15.419

Review 2.  Residue-Specific Peptide Modification: A Chemist's Guide.

Authors:  Justine N deGruyter; Lara R Malins; Phil S Baran
Journal:  Biochemistry       Date:  2017-07-17       Impact factor: 3.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.